Market Place
Sourcing Support
FDA Grants Priority Review For Pierre Fabre`s Tabelecleucel BLA
18 Jul 2024 //
PR NEWSWIRE
FDA Accepts Atara`s BLA For Tab-cel With Priority Review
17 Jul 2024 //
BUSINESSWIRE
Atara Biotherapeutics’ Ebvallo™ Wins Prix Galien Award for Orphan/Rare Diseases
21 Jun 2024 //
BUSINESSWIRE
Atara Submits Tab-cel BLA For Transplant Lymphoproliferative Disease
20 May 2024 //
BUSINESSWIRE
Pierre Fabre announces the submission by Atara of Tabelecleucel (Tab-cel®)
20 May 2024 //
PR NEWSWIRE
Pierre Fabre`s Ebvallo (tabelecleucel) Receives Approval in Europe
10 Mar 2023 //
EMA
Pierre Fabre`s Ebvallo (Tabelecleucel) Approved In Europe
16 Feb 2023 //
EMA
Pierre Fabre to Commercialize Approved Allogeneic T-cell Immunotherapy in Europe
08 Feb 2023 //
BUSINESSWIRE
Atara Biotherapeutics Ebvallo (tabelecleucel) Receives Approval in Europe
13 Jan 2023 //
FDA
Ebvallo`s Tabelecleucel Receives Approval in Europe
12 Jan 2023 //
EMA
Atara`s Ebvallo (tabelecleucel) Receives Approval in Europe
12 Jan 2023 //
EMA
Atara makes history with world-first nod for allogeneic T-cell therapy Ebvallo
20 Dec 2022 //
FIERCEPHARMA
Atara Biotherapeutics` Ebvallo Receives European Commission Approval
19 Dec 2022 //
BUSINESSWIRE
Imbrium Therapeutics Presents Results of a Phase 2 Study of Sunobinop
12 Dec 2022 //
BUSINESSWIRE
Atara Biotherapeutics Presents Data from Pivotal Phase 3 Trial of Tab-cel at ASH
12 Dec 2022 //
BUSINESSWIRE
CHMP offers +ve opinion for two high-profile drugs- latest batch recommendations
15 Oct 2022 //
ENDPTS
Atara to Receive Payment Under Updated Tab-cel Agreement with Pierre Fabre
28 Sep 2022 //
PRESS RELEASE
Atara Biotherapeutics to Announce 2nd Quarter 2022 Financial Results
01 Aug 2022 //
BUSINESSWIRE
With PhIII data in hand, Atara eyes a submission to treat transplant patients
14 Dec 2021 //
ENDPTS
Atara and Pierre Fabre Collaborate to Commercialize Tabelecleucel (Tab-cel®)
04 Oct 2021 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.